Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Ani Pharmaceuticals (ANIP) Receivables - Net (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Receivables - Net for 14 consecutive years, with $281.1 million as the latest value for Q4 2025.

  • Quarterly Receivables - Net rose 26.77% to $281.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $281.1 million through Dec 2025, up 26.77% year-over-year, with the annual reading at $281.1 million for FY2025, 26.77% up from the prior year.
  • Receivables - Net hit $281.1 million in Q4 2025 for Ani Pharmaceuticals, up from $252.6 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $281.1 million in Q4 2025 to a low of $91.9 million in Q1 2021.
  • Historically, Receivables - Net has averaged $171.6 million across 5 years, with a median of $169.3 million in 2024.
  • Biggest five-year swings in Receivables - Net: surged 62.35% in 2022 and later decreased 3.95% in 2024.
  • Year by year, Receivables - Net stood at $128.5 million in 2021, then grew by 28.72% to $165.4 million in 2022, then fell by 2.03% to $162.1 million in 2023, then skyrocketed by 36.8% to $221.7 million in 2024, then rose by 26.77% to $281.1 million in 2025.
  • Business Quant data shows Receivables - Net for ANIP at $281.1 million in Q4 2025, $252.6 million in Q3 2025, and $225.7 million in Q2 2025.